Two drugs from Hengrui Medicine have received clinical trial approval
January 22, 2026
Source: drugdu
28
On January 21, Hengrui Medicine issued an announcement stating that its subsidiaries, Shanghai Hengrui Medicine Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for SHR-7787 Injection and Adebelimab Injection, and will conduct clinical trials in the near future.
According to the announcement, SHR-7787 injection is a Class 1 therapeutic biological product.It works by inducing and activating T cells, enabling them to target and kill tumor cells. Adebelimab injection is a humanized anti-PD-L1 monoclonal antibody independently developed by the company. It can block the PD-1/PD-L1 pathway that leads to tumor immune tolerance by specifically binding to PD-L1 molecules, thereby reactivating the anti-tumor activity of the immune system and achieving the purpose of treating tumors.
https://finance.eastmoney.com/a/202601213626206498.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Recombinant Zoster Vaccine (Shingles Vaccine) Receives Clinical Trial Approval Notice January 22, 2026
- HeartCare Medical (06609.HK) Announces NMPA Acceptance of Registration Application for Self-Expanding Intracranial Drug-Eluting Stent January 22, 2026
- Subsidiary’s Drug Production License Changed January 22, 2026
- Sunshine Novo’s Small Nucleic Acid Drug IND Application Accepted; Innovative Drug Pipeline Enters Harvest Phase January 22, 2026
- Big news! Chia Tai Tianqing’s oral GLP-1 has been approved for clinical trials! Can its differentiated “biased” mechanism break through the red ocean market? January 22, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
